Impact of COX2 on Sera Biomarkers From Obese Subjects

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Obesity promotes worse outcome for post-menopausal breast cancer patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• At least 18 years of age

• Post-menopausal as confirmed by medical history

• Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee

Exclusion Criteria:

• Evidence of active cancer (patients with a prior history of malignancy are encouraged to participate, but due to cytokine levels associated with malignancy there must be no evidence of disease)

• Cachexia

• Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)

• Chronic use of aspirin of omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)

• Known hypersensitivity to aspirin and/or omega-3 fatty acids

• Actively receiving a physician-directed regimen of aspirin and/or receiving herapeutic/prophylactic anticoagulation

• Any aspirin or omega-3 free fatty acid supplementation within the last 14 days

• Subjects who are pregnant

• History of medical noncompliance